Genomic companion for biologics
in-line bioreactor monitoring through real time sequencing
The bioproduction challenge
By 2024, forecasts indicate that 50% of the top 100 most prescribed drugs will be biologics, accounting for 32% of the overall pharmaceutical market. Therapeutic progress and patient access to new biotherapies now rely on bioproduction capacity and performance.
We are committed to provide innovative in line biosensors to help researchers to develop new and efficient expression systems, efficiently manage scale up phase, and for pharma company, secure their large production.
Company vocation
GenSensor was founded with a vision to become a game changer in the field of genomic based in-line bioproduction monitoring
Our company combines the development of a robotic device with an advanced analytics software to monitor, characterize, optimize your bioproduction of ATMP and vaccines
Science behind it
Technology
We combine cutting edge fluidics, microfluidics, sample preparation, long-read sequencing and bioinformatics to provide an integrated robot to monitor bioreactors
Bioprocess companion
Choose when to seed / harvest
Monitor product quality, stability
Genomic information of your product/cells
Avoid late lot rejection
Application field
Biotechs developing ATMP
Gene & Cell therapy
Vaccines, viral vectors, RNA vaccines
Other Biotechs using bioreactors
Team
Computational, cellular and molecular biology experts dedicated to better biologicals
Charles HEBERT, PhD
CEO, founder
Jean-Marie CHARPIN, PhD
President, founder
Where in the world
immeuble Asturia Bâtiment C, 4 Rue Edith Piaf, 44800 Saint-Herblain
HQ
6 rue Edouard Nignon, BP 37201, 44372 NANTES Cedex 03